Articles related to RETINA

Alcon has begun the commercial launch of the Unity M surgical microscope, a modular visualization platform designed for anterior and posterior segment surgery that emphasizes enhanced red reflex, color-adjustable illumination, and ophthalmology-specific depth of field.

An early clinical experience report describes how one retina practice integrated photobiomodulation (PBM) for intermediate age-related macular degeneration, highlighting workflow considerations, patient selection challenges, reimbursement issues, and ongoing uncertainty regarding long-term benefit.

Retina practices are adjusting after Good Days funding limitations reduced copay support for some patients requiring chronic anti-VEGF therapy. Medicare Advantage patients appear especially exposed to affordability pressure.

University of Oklahoma researchers identified a photoreceptor lysosomal recycling pathway regulated by PIKfyve. Mouse-model disruption produced photoreceptor degeneration and RPE changes resembling macular degeneration biology.

The FDA approved Lytenava as the first ophthalmic bevacizumab formulation for wet AMD. The decision moves bevacizumab beyond repackaged intravenous use, with launch logistics still pending.

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.